Vutrisiran Dosage
Medically reviewed by Drugs.com. Last updated on Feb 13, 2025.
Applies to the following strengths: 25 mg/0.5 mL
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Amyloidogenic Transthyretin Amyloidosis
Recommended dose: 25 mg administered by subcutaneous injection once every 3 months
Uses: Treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) and cardiomyopathy of wild-type or hATTR in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits in adults.
Renal Dose Adjustments
Mild and Moderate Renal Dysfunction: No adjustment recommended.
Severe Renal Dysfunction and End-Stage Renal Disease: Data not available
Liver Dose Adjustments
Mild Liver Dysfunction: No adjustment recommended.
Moderate and Severe Liver Dysfunction: Data not available
Precautions
CONTRAINDICATIONS: None
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Dialysis
Data not available
Other Comments
Administration advice:
- This drug is for subcutaneous administration only.
- Should be administered by a healthcare professional.
- If a dose is missed, administer as soon as possible and resume dosing every 3 months from the most recently administered dose.
- Consult the manufacturer product information for further preparation and administration instructions.
- Vitamin A supplementation is recommended.
Storage requirements:
- Store at 2C to 30C (36F to 86F) in the original carton until ready for use.
- Do not freeze.
General: To report suspected adverse reactions, contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Monitoring:
- Metabolic: Vitamin A serum levels prior and during treatment
Patient advice:
- Read the Patient Information and Instructions for Use.
- Female patients should inform their healthcare provider if they are pregnant or planning to become pregnant while taking this drug.
- Patients should contact their healthcare provider if they experience ocular symptoms suggestive of vitamin A deficiency such as night blindness.
More about vutrisiran
- Compare alternatives
- Reviews (1)
- Side effects
- During pregnancy
- Drug class: miscellaneous metabolic agents
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
See also:
Vyndamax
Vyndamax may be given to reduce death or hospitalization caused by heart problems in adults with ...
Amvuttra
Amvuttra is used to treat polyneuropathy associated with hereditary transthyretin-mediated ...
Wainua
Wainua (eplontersen) is used to treat polyneuropathy of hereditary transthyretin-mediated ...
Vyndaqel
Vyndaqel (tafamidis meglumine) is a transthyretin stabilizer that may be given to reduce death or ...
Onpattro
Onpattro is used to treat polyneuropathy in adults with hereditary transthyretin-mediated ...
Tegsedi
Tegsedi (inotersen) is an RNA-targeting treatment that may be used to reduce the symptoms of ...
Patisiran
Patisiran (brand name Onpattro) is an injectable treatment for polyneuropathy caused by hereditary ...
Eplontersen
Eplontersen (Wainua) is used to treat polyneuropathy of hereditary transthyretin-mediated ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.